VacV Biotherapeutics
June 24, 2026
Theater 1
Type: Company Presentation
Focus Area:
Oncology
VacV Biotherapeutics is headquartered in London and sources novel research and therapeutic concepts from Barts Cancer Institute, London, UK. We now have an R&D center at BioBay in Suzhou, China, and aims to expand globally.
We have established two core oncolytic immunotherapy platforms based on genetically engineered adenovirus (AdV) and systemically deliverable vaccinia virus (VV), focusing on the treatment of CNS malignancies (e.g., glioblastoma and pediatric intrinsic pontine glioma) and refractory/metastatic solid tumors. Our unique operational model combines the efficiency advantages of early-stage R&D in China with the capabilities of late-stage global clinical development. Notably, our lead product BioTTT001 has shown dramatic efficacy in patients with recurrent GBM and DIPG.
Company HQ City:
Londo
Company HQ State:
United Kingdom
Company HQ Country:
United Kingdom
Year Founded:
2022
Lead Product in Development:
• Lead product BioTTT001 with dramatic efficacy data:
13% complete response rate in recurrent Glioblastoma(rGBM) patients;
Stopped progression in 86% of treated rGBM patients;
54% long-survival(≥18 months) rate when combining with anti-PD-1;
Effective in 89% of treated young patients with diffuse intrinsic pontine glioma(DIPG);
CEO
Yidan Zhang MD MBA
www.linkedin.com/in/yidan-zhang-md-mba-7890a681
Development Phase of Lead Product
Phase II
Number of Unlicensed Products Looking for Licensing
Three
When you expect your next catalyst update?
2026 Q3
What is your next catalyst (value inflection) update?
FDA IND clearance of Phase 1b/2 study in recurrent Glioblastoma with pivotal intent
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}